Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label, Multicenter, Trial of JNJ-42756493 In Combination With Dexamethasone For The Treatment Of FGFR3 Wild-type Or Mutation Positive Relapsed and/or Refractory Multiple Myeloma

NCT02952573 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT02952573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02952573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label, Multicenter, Trial of JNJ-42756493 In Combination With Dexamethasone For The Treatment Of FGFR3 Wild-type Or Mutation Positive Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Terminated
Start date
June 13, 2017
Completion date
November 13, 2018
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, relapsed/refractory